comparemela.com

Latest Breaking News On - Mosunetuzumab - Page 1 : comparemela.com

Choosing Bispecific T-cell Engager as Third-line and Beyond Therapy for FL

A panel of experts discuss how to choose bispecific T-cell engagers as third-line and beyond therapy for FL.

Recent updatesFollicular lymphomaMantle cell lymphomaBispecifict cell engagerBeyond therapyThird lineT cell engagerLarge cell lymphomaDosing scheduleStep up dosingSplit dosing

Bispecific T-cell Engagers as Third-line and Beyond Therapy for FL

Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.

Matthew lunningRecent updatesFollicular lymphomaMantle cell lymphomaT cell engagersBeyond therapyBispecifict cell engagersThird line and beyondThird line therapyT cell engagerFollicular lymphoma treatmentFl treatmentStep up dosing

Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study

Elizabeth Budde, MD, PhD, presents data from the 3-year follow-up from a pivotal phase II study investigating mosunetuzumab monotherapy in patients with relapsed and/or refractory follicular lymphoma after ≥2 prior therapies.

San diegoUnited statesElizabeth buddeDemonstrate durable responsesRefractory follicular lymphomaYear follow upPivotal phasePartnership withIndependent review committeeFollicular lymphomaRelapsed refractory follicular lymphomaBispecific antibodyBispecifict cell engagerPivotal phase ii study

Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients With Relapsed/Refractory LBCL: Primary Analysis of a Phase Ib/II Study

Elizabeth Budde, MD, PhD, presents data from on mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma.

Mosunetuzumab mosunInternational prognostic indexClin oncolBlood marrow transplantAnn arborLargeb cell lymphomaPolatuzumab vedotinRelapsed refractory lbclRelapsed refractory largeb cell lymphomaOverall response rate

Olszewski Recaps Results of Mosunetuzumab in Elderly/Unfit DLBCL

Adam J. Olszewski, MD, discusses the promising results of a phase 1b/2 study of mosunetuzumab for elderly/unfit patients with previously untreated diffuse large B-cell lymphoma.

Brown universityRhode islandUnited statesRhode island hospitalAdamj olszewskiAdamj olszewskiElderly unfit patients with previously untreated diffuse largeb cell lymphomaDiffuse largeb cell lymphomaPhase 1b 2 study nct03677154

vimarsana © 2020. All Rights Reserved.